Alphatec Holdings, Inc. Announces Sales Launch in Europe

CARLSBAD, Calif., June 6, 2008 (PRIME NEWSWIRE) -- Alphatec Holdings, Inc.
(Nasdaq:ATEC), a leading medical technology company focused on the design,
development, manufacturing and marketing of products for the surgical treatment
of spine disorders, announced that its subsidiary, Alphatec Spine, Inc., has
received its first binding sales order in connection with its spinal products
launch in the European market. Alphatec anticipates shipping products related to
such order prior to the end of this month.

"We indicated earlier this year that we would be launching in Europe and we are
enthusiastic about receiving this significant sales order," said Dirk Kuyper,
Alphatec's President and Chief Executive Officer. "Alphatec is a global brand
with highly respected products and we are pleased to serve the European surgeon
and patient populations. The European sales channel provides a tremendous
opportunity for Alphatec. I anticipate our sales growth to continue through
increased market penetration and the launch of new products over the coming
year."

About Alphatec

Alphatec Holdings, Inc. (Nasdaq:ATEC) designs, develops, manufactures and
markets products for the surgical treatment of spine disorders. Alphatec's broad
product portfolio and pipeline includes a variety of spinal implant products and
systems focused on solutions addressing the cervical, thoracolumbar,
intervertebral, minimally invasive, vertebral compression fracture and allograft
markets. Alphatec's "surgeons' culture" emphasizes collaboration with spinal
surgeons to conceptualize, design and co-develop a broad range of products.
State-of-the-art in-house manufacturing capabilities provide a unique
competitive advantage, enabling Alphatec to rapidly deliver customized solutions
to meet surgeons' and patients' critical needs. Alphatec has 23 issued U.S.
patents, six issued foreign patents and 31 pending patent applications,
including 10 pending U.S. applications, six pending international applications
and 15 pending foreign national applications. Alphatec's principal product
offerings are primarily focused on the global spine implant and biologics
market, which is estimated to be more than $7.0 billion in 2007. In addition to
its U.S. operations, Alphatec also markets a range of spine and orthopedic
products in Asia through its subsidiary, Alphatec Pacific, Inc. For more
information, please visit www.alphatecspine.com.

The Alphatec Holdings, Inc. logo is available at
http://www.primenewswire.com/newsroom/prs/?pkgid=3520

Forward Looking Statements

This press release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks and
uncertainty. Such statements are based on management's current expectations and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These forward-looking statements include, but are not limited to
Alphatec's ability to ship products related to its European launch in a timely
manner, and Alphatec's ability to obtain increased market penetration in Europe
as a result of new product launches or otherwise. Alphatec cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: uncertainty of success in developing new products or products
currently in Alphatec's pipeline, uncertainty of success in bringing to market
differentiated products that meet the evolving needs of spine surgeons,
patients, and healthcare providers, failure to obtain FDA clearance or approval
for new products, Alphatec's ability to compete with other competing products
and with emerging new technologies within and outside of spinal fusion,
Alphatec's ability to expand and maintain a successful sales and marketing
organization, Alphatec's ability to maintain its level of previously reported
sales growth, Alphatec's ability to successfully control its costs, Alphatec's
ability to successfully leverage upon the experience of its Scientific Advisory
Board, Alphatec's ability to develop and expand its spine fusion business in the
United States, Asia and Europe, continuation of favorable third party payor
reimbursement for procedures performed using Alphatec's products, unanticipated
expenses or liabilities or other adverse events affecting cash flow or
Alphatec's ability to successfully control its costs or achieve profitability,
uncertainty of additional funding, product liability exposure, patent
infringement claims and claims related to Alphatec's intellectual property.
Please refer to the risks detailed from time to time in Alphatec's SEC reports.
Alphatec disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

-0-
CONTACT: Alphatec Holdings, Inc.
Dirk Kuyper, President and CEO
760.494.6631
dkuyper@alphatecspine.com